Form 4: Apogee CFO Sells Shares Under Pre-Arranged Plan

Apogee Therapeutics' Chief Financial Officer, Jane Henderson, sold 1,500 shares of common stock for $80 per share on December 19, 2025, as part of a Rule 10b5-1 trading plan.

Summary

• Jane Henderson, Chief Financial Officer of Apogee Therapeutics, Inc. (APGE), reported a sale of common stock.
• The transaction involved the disposition of 1,500 shares of common stock.
• The shares were sold at a price of $80 per share.
• The transaction date was December 19, 2025.
• This sale was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2024.
• Following this transaction, Jane Henderson beneficially owns 193,371 shares of Apogee Therapeutics common stock directly.

Sentiment

Score: 5

Explanation: The filing reports a routine, pre-scheduled insider stock sale under a 10b5-1 plan, which is generally considered neutral news and does not reflect positively or negatively on the company's operational performance or future prospects.

Future Outlook

This filing does not provide any forward-looking statements or guidance regarding the company's future performance.

Industry Context

This insider transaction is a routine disclosure and does not provide specific insights into broader industry trends or competitive landscape.

Stakeholder Impact

• The sale of 1,500 shares by the Chief Financial Officer is a minor transaction relative to the company's total outstanding shares and is unlikely to have a significant impact on shareholders, employees, customers, suppliers, or creditors.

Key Dates

Keywords

Apogee Therapeutics, APGE, Insider Trading, Form 4, Jane Henderson, Chief Financial Officer, Stock Sale, 10b5-1 Plan, Equity Transaction